Disclaimer

Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.

US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.
Videos

TAVR for Aortic Regurgitation: The Completion of the ALIGN-AR Study and the Future Paradigm of AR Treatment

Torsten Vahl, Rebecca Hahn, Vinod Thourani, Raj Makkar and Marty Leon discuss TAVR for Aortic Regurgitation at TCT 2022.

Latest News

View All
Press
JenaValve Announces Start of Commercialization of the Trilogy<sup>®</sup> Transcatheter Heart Valve System in the US
April 1, 2026
JenaValve Announces Start of Commercialization of the Trilogy® Transcatheter Heart Valve System in the US
Read More
Press
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System
March 18, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System
Read More
Press
New, Late-Breaking Results from the ALIGN-AR Trial Published in The Lancet and Presented at PCR London Valves
November 24, 2025
New, Late-Breaking Results from the ALIGN-AR Trial Published in The Lancet and Presented at PCR London Valves
Read More
Close Download
The information in this Reimbursement Guide is provided for educational purposes only and is not intended to be coding or billing advice. This coding information is based upon publicly available information and is current as of April 1, 2026 and subject to change without notice. JenaValve Technology, Inc. cannot guarantee that any product or service billed with the codes listed will be covered or, if covered, the listed payment amount will be paid by any payer. It is the responsibility of the provider to select appropriate codes for each patient and to submit appropriate codes, charges, and modifiers for services rendered. Providers should contact insurers to verify correct coding procedures prior to submitting claims related to the use of JenaValve products. In all cases, providers must bill according to the rules, policies and procedures of individual payers. The medical record should document that the product or procedure was medically necessary and furnished or performed as reported. Clinical need, not reimbursement amount, should always drive clinical decision making. If you have any questions about appropriate billing for products or services, please consult your local payer. The information contained in this guide is provided to assist providers in understanding the reimbursement process. It is intended to assist providers in obtaining accurate and appropriate reimbursement for the healthcare services provided. It is not intended to increase or maximize reimbursement by any payer. It is strongly recommended that providers consult with their payer organizations with regard to local reimbursement policies. The information contained herein is provided for information purposes only and represents no statement, promise, or guarantee by JenaValve Technology, Inc. concerning levels of reimbursement, payment, or charge. Similarly, all CPT codes are supplied for information purposes only and represent no statement, promise, or guarantee by JenaValve Technology, Inc. that these codes will be appropriate or that reimbursement will be made. For additional information, please contact us at reimbursement.usa@jenavalve.com.